Genomics Biotech

How Generate Biomedicines uses generative AI to design protein therapeutics and advance candidates like GB-0895, GB-4362 and GB-5267 into the clinic.

A concise look at how AI is accelerating drug discovery, refining diagnostics, and enabling personalized medicine with examples from AlphaFold and generative drug design.

BioSee AI from the University of Nottingham uses ultrasonic and optical sensing with machine learning to deliver affordable, non-invasive real-time bioprocess monitoring for biomanufacturers.

Eli Lilly teams with Nvidia to build Lillypod, a supercomputer strategy to speed AI-driven drug discovery and reshape the pharmaceutical lifecycle.

Agentic AI forms collaborative in silico teams that speed drug discovery, biomarker discovery and data analysis while raising validation and governance questions.

A concise, expert overview of how AI differs from machine learning and how it accelerates drug discovery, diagnostics, and personalized treatment in biotech.

AI-enabled vascular grafts monitor blood flow in real time to detect blockages early and improve post-op care for vascular surgery patients.

At JPM 2026 Bora Pharmaceuticals and EirGenix unveiled AI-driven manufacturing, US onshoring, continuous production and biosimilar partnerships reshaping Taiwan’s biopharma role.

Insilico Medicine and Qilu Pharmaceutical launch an AI-driven collaboration worth up to $120M to discover small molecules for cardiometabolic diseases.

AI-driven drug discovery, lower rates and a looming patent cliff are set to accelerate biotech M&A in 2026. What investors and executives should watch.